10X Genomics Inc reports results for the quarter ended in September - Earnings Summary

10x Genomics

02/11/2023 21:57

* 10X Genomics Inc  TXG.OQ  reported a quarterly adjusted
loss
of 79 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of -37 cents.  The mean expectation of fourteen analysts for
the quarter was for a loss of 46 cents per share. Wall Street
expected results to range from -58 cents to -32 cents per share.
    * Revenue rose 17.2% to $153.64 million from a year ago;
analysts
expected $151.26 million. 
    * 10X Genomics Inc's reported EPS for the quarter was a loss
of 79
cents​.
    * The company reported a quarterly loss of $92.99 million.
    * 10X Genomics Inc shares had fallen by 16.8% this
quarter and
lost 5.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 25.4%
in the last three months.​ 
    * In the last 30 days, four analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for 10X Genomics Inc
is $65.00 
This summary was machine generated from LSEG data November 2 at
09:56 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.46          -0.79          Missed
 Jun. 30 2023      -0.40          -0.53          Missed
 Mar. 31 2023      -0.37          -0.44          Missed
 Dec. 31 2022      -0.31          -0.15          Beat